Clinical trials: Elevated Risk of Cardiovascular Disease
Myocardial Infarction
Studying the Effectiveness of Early Invasive Treatment in Elderly Patients With High-risk Non-ST-segment Elevation Acute Coronary Syndrome.
The goal of this is observational study is to compare about MACE events and predisposing factors related to MACE events in elderly patients with high-risk non-ST acute coronary syndromes receiving early versus late invasive…
- Trial name
- NCT06486233
- Where
- Vietnam
- Volunteers
- 385 people
- Sponsor
- Gia Dinh People Hospital
Bleeding, Thrombosis
Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery
Patients who have undergone placement of coronary stents require dual antiplatelet therapy with Plavix and aspirin to prevent the serious complication of in-stent thrombosis.
- Trial name
- NCT00653601
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
This phase I trial studies the side effects and best dose of lenalidomide after donor stem cell transplant and bortezomib in treating patients with high-risk multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01954784
- Testing
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Hypertension, Left Ventricular Hypertrophy
Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension
Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without LVH.
- Trial name
- NCT00139555
- Testing
- amlodipine/benazepril
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Novartis
Sodium Excess, Racial Disparities
Vascular Effects of Acute Sodium (VEAS) Study
This IRB will cover a current clinical trial (NCT04244604) that was started at Auburn University (AU IRB#19-390), the Principal Investigator's prior institution, and is supported by his NIH Career Development Award (NHLBI…
- Conditions
- Sodium Excess, Racial Disparities, Blood Pressure, Cardiovascular Risk Factor
- Trial name
- NCT04244604
- Testing
- Low Sodium Meal (140 mg sodium chloride), High Sodium Meal (2500 mg sodium chloride)
- Where
- 2 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Indiana University
High Risk Hypertensive Patients
Study to Improve Quality of Care and Patient Health in the Field of Cardiovascular Risk Factors in General Practice
Observational studies performed in France and abroad in hypertensive patients at high cardiovascular risk have shown a wide gap between the therapeutic targets reached in ambulatory patients and those set by guidelines.
- Trial name
- ESCAPE (NCT00348855)
- Testing
- Cardiovascular drugs strategies, Compliance, Exercise
- Where
- 2 sites in France
- Volunteers
- 1,836 people
- Sponsor
- Collège National des Généralistes Enseignants
Stroke, Atherosclerosis
ParisK: Validation of Imaging Techniques
The possibility of the identification of the risk of rupture of a carotid plaque will have tremendous impact in clinical decision making.
- Trial name
- ParisK (NCT01208025)
- Testing
- Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)
- Where
- 4 sites in Netherlands
- Volunteers
- 244 people
- Sponsor
- Maastricht University Medical Center
Congestive Heart Failure, Asthma
Remote Monitoring of High-Risk Patients With Chronic Cardiopulmonary Diseases
In this project, Institute of Bioengineering \& Bioimaging (IBB), A*STAR would like to collaborate with Massachusetts General Hospital to aggregate patient data and to further develop its software algorithm using machine learning…
- Conditions
- Congestive Heart Failure, Asthma, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis
- Trial name
- NCT04825067
- Testing
- Respiratory Sensor measurements
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Institute of Bioengineering and Bioimaging (IBB)
Cardiovascular Diseases
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective…
- Trial name
- NCT00153101
- Testing
- Telmisartan, Combination of Telmisartan and Ramipril, Ramipril
- Where
- 732 sites in United States, Argentina and 39 more
- Volunteers
- 31,546 people
- Sponsor
- Boehringer Ingelheim
Infant Development, Infant,Premature
Pacifier Activated Device and Mother's Voice in Infants at High-risk for Cerebral Palsy
The study seeks to determine the efficacy of non-nutritive suck (NNS) training using a pacifier-activated device (PAM) with mothers' voice to condition suck-strength and rhythmicity, in improving the feeding and developmental…
- Conditions
- Infant Development, Infant,Premature, Hydrocephalus, Neonatal Encephalopathy
- Trial name
- NCT03230032
- Testing
- pacifier-activated device
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Nationwide Children's Hospital
Coronary Artery Disease, Myocardial Infarction
Prediction of Recurrent Events With 18F-Fluoride
This is a multi-centre observational study. It will make use of the positron emission tomography (PET) tracer 18F-sodium fluoride (18F-NaF) as a marker of coronary plaque vulnerability to detect culprit and non-culprit unstable…
- Trial name
- PREFFIR (NCT02278211)
- Where
- United Kingdom
- Volunteers
- 995 people
- Sponsor
- University of Edinburgh
Myocardial Infarction (MI), Perioperative Myocardial Injury
High-Sensitivity Troponin T Kinetics and 30-Day Outcomes After Major Abdominal Surgery (TROP-MAS)
Major abdominal surgery (MAS) carries a high risk of 30-day mortality (>5%). Perioperative myocardial injury (PMI) and myocardial injury after noncardiac surgery (MINS) frequently develop asymptomatically due to surgical…
- Conditions
- Myocardial Infarction (MI), Perioperative Myocardial Injury, Sepsis, Digestive System Surgical Procedures
- Trial name
- TROP-MAS (NCT07850492)
- Testing
- High-sensitivity cardiac troponin T (hs-cTnT) surveillance
- Where
- Vietnam
- Volunteers
- 650 people
- Sponsor
- Bach Mai Hospital
Coronary Arterial Disease (CAD), Acute Coronary Syndromes
Identification Of High-risk Coronary Plaques By Multimodal Intravascular Imaging
This study is a multicenter prospective observational clinical study, which will be conducted in 11 hospitals, and approximately 500 subjects will be enrolled.
- Trial name
- PlaqueVision (NCT06681155)
- Testing
- Assessment of plaque morphology, structure, and stability in non-culprit lesions
- Where
- 11 sites in China
- Volunteers
- 500 people
- Sponsor
- Chinese PLA General Hospital
Cardiovascular Risk Factor, Cardiovascular Disease
Training Programme in Physical Activity
The primary prevention of cardiovascular disease is an unresolved health problem. A sedentary lifestyle and a low cardiorespiratory condition both increase the risk of cardiovascular disease, at a similar extent as that promoted…
- Trial name
- NCT03717363
- Testing
- Training programme, Educational talk
- Where
- Spain
- Volunteers
- 147 people
- Sponsor
- Hospital Mutua de Terrassa
Carotid Artery Disease
CHOICE: Carotid Stenting For High Surgical-Risk Patients
The purposes of this study is to 1) Provide additional information that the commercially available Abbott Vascular Carotid Stent Systems and Embolic Protection Systems can be used successfully by a wide range of physicians under…
- Trial name
- NCT00406055
- Testing
- RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6
- Where
- United States
- Volunteers
- 18,855 people
- Sponsor
- Abbott Medical Devices
Brugada Syndrome
Hydroquinidine Versus Placebo in Patients With Brugada Syndrome
The specific aim of this study is to determine whether hydroquinidine administration can prevent heart from appearance of ventricular arrhythmia detected by the automatic implantable defibrillator (ICD).
- Trial name
- Quidam (NCT00927732)
- Testing
- hydroquinidine
- Where
- 17 sites in France
- Volunteers
- 64 people
- Sponsor
- Nantes University Hospital
Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)
The research team is conducting a randomized, double-blind, placebo-controlled, multicenter clinical study aimed at evaluating the impact of adding Tolecilimab (a PCSK9 inhibitor) to standard lipid-lowering therapy (statins ±…
- Trial name
- NCT07341958
- Testing
- Tafolecimab
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Beijing Tiantan Hospital
Covid19, Atherosclerosis
A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults
MITIGATE is a prospective, open-label, parallel-group, randomized, pragmatic clinical trial. The MITIGATE Study has been designed to evaluate the real-world clinical effectiveness of pre-treatment with icosapent ethyl (IPE), also…
- Conditions
- Covid19, Atherosclerosis, Cardiovascular Diseases, Upper Respiratory Tract Infections
- Trial name
- MITIGATE (NCT04505098)
- Testing
- Icosapent ethyl
- Where
- United States
- Volunteers
- 39,600 people
- Sponsor
- Kaiser Permanente
Hypercholesterolemia
Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
- Trial name
- NCT01507831
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 320 sites in United States, Argentina and 25 more
- Volunteers
- 2,341 people
- Sponsor
- Sanofi
Hypertension, Condition
Adaptive Cognitive Training on Cognitive Function in Elderly Hypertension Patients in the Community
Objective A growing body of evidence supports hypertension as a risk factor for cognitive decline. Hypertension is significantly associated with accelerated cognitive decline, poorer cognitive function, and mild cognitive…
- Conditions
- Hypertension, Condition, Aging
- Trial name
- NCT06512922
- Testing
- adaptive cognitive training
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.